CN107206064B - 癌症对通过pd-1阻断实现的免疫疗法响应的决定因素 - Google Patents

癌症对通过pd-1阻断实现的免疫疗法响应的决定因素 Download PDF

Info

Publication number
CN107206064B
CN107206064B CN201580073049.2A CN201580073049A CN107206064B CN 107206064 B CN107206064 B CN 107206064B CN 201580073049 A CN201580073049 A CN 201580073049A CN 107206064 B CN107206064 B CN 107206064B
Authority
CN
China
Prior art keywords
cancer
patients
response
mutations
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580073049.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN107206064A (zh
Inventor
T·A·陈
N·A·里兹维
M·D·赫尔曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Priority to CN202210026426.9A priority Critical patent/CN114672559A/zh
Publication of CN107206064A publication Critical patent/CN107206064A/zh
Application granted granted Critical
Publication of CN107206064B publication Critical patent/CN107206064B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201580073049.2A 2014-11-21 2015-11-23 癌症对通过pd-1阻断实现的免疫疗法响应的决定因素 Active CN107206064B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210026426.9A CN114672559A (zh) 2014-11-21 2015-11-23 癌症对通过pd-1阻断实现的免疫疗法响应的决定因素

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462083088P 2014-11-21 2014-11-21
US62/083,088 2014-11-21
US201562132381P 2015-03-12 2015-03-12
US62/132,381 2015-03-12
PCT/US2015/062208 WO2016081947A2 (en) 2014-11-21 2015-11-23 Determinants of cancer response to immunotherapy by pd-1 blockade

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202210026426.9A Division CN114672559A (zh) 2014-11-21 2015-11-23 癌症对通过pd-1阻断实现的免疫疗法响应的决定因素

Publications (2)

Publication Number Publication Date
CN107206064A CN107206064A (zh) 2017-09-26
CN107206064B true CN107206064B (zh) 2021-12-21

Family

ID=56014697

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202210026426.9A Pending CN114672559A (zh) 2014-11-21 2015-11-23 癌症对通过pd-1阻断实现的免疫疗法响应的决定因素
CN201580073049.2A Active CN107206064B (zh) 2014-11-21 2015-11-23 癌症对通过pd-1阻断实现的免疫疗法响应的决定因素

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202210026426.9A Pending CN114672559A (zh) 2014-11-21 2015-11-23 癌症对通过pd-1阻断实现的免疫疗法响应的决定因素

Country Status (9)

Country Link
US (3) US20180291074A1 (enExample)
EP (2) EP4393546A3 (enExample)
JP (4) JP7173733B2 (enExample)
CN (2) CN114672559A (enExample)
AU (3) AU2015349644B2 (enExample)
CA (1) CA2968059A1 (enExample)
HK (1) HK1244440A1 (enExample)
MA (1) MA40737A (enExample)
WO (1) WO2016081947A2 (enExample)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8217149B2 (en) 2008-12-09 2012-07-10 Genentech, Inc. Anti-PD-L1 antibodies, compositions and articles of manufacture
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
WO2016069727A1 (en) 2014-10-29 2016-05-06 Five Prime Therapeutics, Inc. Combination therapy for cancer
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
GB201516047D0 (en) 2015-09-10 2015-10-28 Cancer Rec Tech Ltd Method
US20170199961A1 (en) 2015-12-16 2017-07-13 Gritstone Oncology, Inc. Neoantigen Identification, Manufacture, and Use
AU2017205270B2 (en) 2016-01-08 2024-01-18 Nykode Therapeutics ASA Therapeutic anticancer neoepitope vaccine
KR102500659B1 (ko) 2016-02-29 2023-02-16 제넨테크, 인크. 암에 대한 치료 및 진단 방법
WO2017151517A1 (en) 2016-02-29 2017-09-08 Foundation Medicine, Inc. Methods of treating cancer
EP3804620B1 (en) * 2016-03-01 2022-02-16 North Carolina State University Enhanced cancer immunotherapy by microneedle patch-assisted delivery
CN116059325B (zh) * 2016-03-02 2025-12-05 东丽株式会社 免疫诱导剂
KR20230091191A (ko) 2016-05-27 2023-06-22 아게누스 인코포레이티드 항-tim-3 항체 및 이의 사용 방법
JP6910653B2 (ja) * 2016-07-01 2021-07-28 国立大学法人東北大学 免疫チェックポイント阻害薬使用における免疫関連副作用の予測方法
SG11201901432YA (en) * 2016-08-25 2019-03-28 Nantomics Llc Immunotherapy markers and uses therefor
MX2019003934A (es) * 2016-10-06 2019-07-10 Genentech Inc Métodos terapéuticos y de diagnóstico para el cáncer.
US11515008B2 (en) 2016-10-07 2022-11-29 Omniseq, Inc. Methods and systems for determining personalized t'herapies
US20190369096A1 (en) * 2017-01-13 2019-12-05 Nantbio, Inc. Validation of neoepitope-based treatment
US12331359B2 (en) 2017-01-18 2025-06-17 Michael Laessig Neoantigens and uses thereof for treating cancer
EA201991804A1 (ru) 2017-02-01 2020-02-07 МОДЕРНАТиЭкс, ИНК. ИММУНОМОДУЛИРУЮЩИЕ ТЕРАПЕВТИЧЕСКИЕ КОМПОЗИЦИИ мРНК, КОДИРУЮЩЕЙ ПЕПТИДЫ С АКТИВИРУЮЩЕЙ ОНКОГЕННОЙ МУТАЦИЕЙ
WO2018145023A1 (en) * 2017-02-06 2018-08-09 Novartis Ag Method of predicting response to immunotherapy
US20190360051A1 (en) * 2017-02-17 2019-11-28 Stichting Vumc Swarm intelligence-enhanced diagnosis and therapy selection for cancer using tumor- educated platelets
MX2019011148A (es) * 2017-03-20 2019-10-17 Genocea Biosciences Inc Metodos de tratamiento.
SG10202110594UA (en) * 2017-03-31 2021-11-29 Bristol Myers Squibb Co Methods of treating tumor
GB201710815D0 (en) * 2017-07-05 2017-08-16 Francis Crick Inst Ltd Method
IL271888B2 (en) * 2017-07-21 2024-09-01 Genentech Inc Therapeutic and diagnostic methods for cancer
KR20200033930A (ko) * 2017-07-28 2020-03-30 브리스톨-마이어스 스큅 컴퍼니 체크포인트 억제제에 대한 예측성 말초 혈액 바이오마커
SG11202001606XA (en) * 2017-09-13 2020-03-30 Five Prime Therapeutics Inc Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer
WO2019055860A1 (en) * 2017-09-15 2019-03-21 The Texas A&M University System METHODS FOR IMPROVING IMMUNOTHERAPY IN THE TREATMENT OF CANCER
AU2018338441B2 (en) * 2017-09-25 2025-08-14 Memorial Sloan Kettering Cancer Center Tumor mutational load and checkpoint immunotherapy
WO2019070769A1 (en) * 2017-10-02 2019-04-11 Curematch, Inc. METHOD FOR PREDICTING ANTIGENICITY AND / OR IMMUNOGENICITY OF A TUMOR DERIVED NEO-PEPTIDE USING MUTATIONAL SIGNATURE PATTERNS
CN118888004A (zh) 2017-10-10 2024-11-01 磨石生物公司 使用热点进行的新抗原鉴别
CA3077221A1 (en) 2017-10-12 2019-04-18 Nantomics, Llc Cancer score for assessment and response prediction from biological fluids
EP3694884A1 (en) 2017-10-15 2020-08-19 Bristol-Myers Squibb Company Methods of treating tumor
JP7421474B2 (ja) 2017-11-03 2024-01-24 ガーダント ヘルス， インコーポレイテッド 腫瘍遺伝子変異量の正規化
WO2019095017A1 (en) * 2017-11-17 2019-05-23 Gmdx Co Pty Ltd Systems and methods for predicting the efficacy of cancer therapy
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
US12367978B2 (en) 2017-12-01 2025-07-22 Illumina, Inc. Methods and systems for determining somatic mutation clonality
CA3099057C (en) * 2018-05-03 2023-09-19 Aarthi Balasubramanyam Surrogate marker and method for tumor mutation burden measurement
KR20210006405A (ko) * 2018-05-04 2021-01-18 메르크 파텐트 게엠베하 암의 치료를 위한 PD-1/PD-L1, TGFβ 및 DNA-PK의 조합 억제
CN112752854B (zh) 2018-07-23 2025-03-18 夸登特健康公司 用于通过肿瘤分数和覆盖率调整肿瘤突变负荷的方法和系统
WO2020021119A1 (en) 2018-07-27 2020-01-30 F. Hoffmann-La Roche Ag Method of monitoring effectiveness of immunotherapy of cancer patients
WO2020045479A1 (ja) * 2018-08-29 2020-03-05 公益財団法人東京都医学総合研究所 ＨＧＦ－ｒｅｇｕｌａｔｅｄ ｔｙｒｏｓｉｎｅ ｋｉｎａｓｅ ｓｕｂｓｔｒａｔｅ（ＨＧＳ）を標的とした抗腫瘍剤
JP7539367B2 (ja) 2018-08-31 2024-08-23 ガーダント ヘルス， インコーポレイテッド 無細胞ｄｎａにおけるマイクロサテライト不安定性の検出
WO2020102674A1 (en) * 2018-11-15 2020-05-22 Personal Genome Diagnostics Inc. Method of improving prediction of response for cancer patients treated with immunotherapy
EP3893932A4 (en) * 2018-12-12 2022-09-07 Medimmune, LLC BLOOD-BASED TUMORMUTATION LOAD AS A PREDICTOR OF OVERALL SURVIVAL IN NON-SMALL CELL LUNG CANCER
EP3982954A4 (en) 2019-06-14 2024-01-03 The Trustees of Columbia University in the City of New York NT5C2 INHIBITORS FOR THE TREATMENT OF CHEMOTHERAPY-RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIA
AU2020376937A1 (en) * 2019-11-01 2022-06-09 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. HLA class I sequence divergence and cancer therapy
GB202003669D0 (en) * 2020-03-13 2020-04-29 Univ Oxford Innovation Ltd Method for identifying neo-antigens
EP4143345A1 (en) * 2020-04-28 2023-03-08 Genentech, Inc. Methods and compositions for non-small cell lung cancer immunotherapy
CN116529835A (zh) * 2020-06-01 2023-08-01 Gmdx私人有限公司 预测癌症进展的方法
CN112309502B (zh) * 2020-10-14 2024-09-20 深圳市新合生物医疗科技有限公司 一种计算肿瘤新抗原负荷的方法及系统
CA3200667A1 (en) * 2020-11-06 2022-05-12 The General Hospital Corporation Methods for characterizing biological samples
US20240238340A1 (en) * 2021-05-03 2024-07-18 Rutgers, The State University Of New Jersey Immunotherapy for inflammatory bowel disease and/or cancer
CN113030475B (zh) * 2021-05-25 2021-08-10 泛肽生物科技(浙江)有限公司 一种基于细胞线粒体质量评估的t细胞pd-1检测方法
CN113355424B (zh) * 2021-07-14 2022-03-25 江苏先声医学诊断有限公司 Pcdh11x突变在预测非小细胞肺癌患者对免疫检查点抑制剂疗法敏感性中的应用
WO2024216165A1 (en) 2023-04-12 2024-10-17 Icahn School Of Medicine At Mount Sinai Computational methods for selecting personalized neoantigen vaccines

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102713606A (zh) * 2009-11-13 2012-10-03 无限制药股份有限公司 用于鉴定、评估、预防和治疗癌症的组合物、试剂盒和方法
CN103154034A (zh) * 2010-04-13 2013-06-12 塞尔德克斯医疗公司 结合人cd27的抗体及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033497A1 (en) 2002-08-13 2004-02-19 Alarcon-Riquelme Marta E. Polymorphisms of PD-1
TWI477602B (zh) 2006-02-09 2015-03-21 Educational Foundation Jichi Medical Univ Novel viral vector
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
ES3038392T3 (en) * 2010-05-14 2025-10-13 Massachusetts Gen Hospital Neoantigen specific cytotoxic t cells for use in treating cancer
US20130225433A1 (en) * 2012-02-29 2013-08-29 The Regents Of The Universitys Of Michagan Prostate cancer markers and uses thereof
NZ701324A (en) 2012-05-04 2016-09-30 Pfizer Prostate-associated antigens and vaccine-based immunotherapy regimens
ES2737757T3 (es) 2012-09-28 2020-01-15 Univ Connecticut Identificación de epítopos protectores contra tumores para el tratamiento de cánceres
AU2014374020A1 (en) * 2014-01-02 2016-08-18 Memorial Sloan Kettering Cancer Center Determinants of cancer response to immunotherapy
KR20170080697A (ko) * 2014-11-13 2017-07-10 더 존스 홉킨스 유니버시티 관문 차단 및 미소부수체 불안정성
MA40737A (fr) 2014-11-21 2017-07-04 Memorial Sloan Kettering Cancer Center Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
AU2018338441B2 (en) * 2017-09-25 2025-08-14 Memorial Sloan Kettering Cancer Center Tumor mutational load and checkpoint immunotherapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102713606A (zh) * 2009-11-13 2012-10-03 无限制药股份有限公司 用于鉴定、评估、预防和治疗癌症的组合物、试剂盒和方法
CN103154034A (zh) * 2010-04-13 2013-06-12 塞尔德克斯医疗公司 结合人cd27的抗体及其用途

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Exomics and immunogenics;Stephane Champiat et al;《Oncoimmunology》;20140101;第3卷(第1期);第e27817页 *
Genetic Basis for clinical response to CTLA-4 Blockade in Melanoma;Alexandra Snyder et al;《New England Journal of Medicine》;20141119;第371卷(第23期);第2189-2199页 摘要，方法和结果部分；补充材料 *
Merk Melanoma Drug is First PD-1 inhibitor OK’d by FDA;Alex Philippidis;《Genetic Engineering & Biotechnology News》;20140905;全文 *
Safety and tumor reponses with lambrolizumab(Anti-PD-1) in melanoma;Omid Hamid et al;《New England Journal of Medicine》;20130711;第369卷(第2期);第134-144页 *

Also Published As

Publication number Publication date
EP3220950A2 (en) 2017-09-27
AU2021215099A1 (en) 2021-08-26
US12485162B2 (en) 2025-12-02
CN114672559A (zh) 2022-06-28
MA40737A (fr) 2017-07-04
WO2016081947A4 (en) 2016-09-09
JP7550193B2 (ja) 2024-09-19
AU2024278364A1 (en) 2025-02-13
HK1244440A1 (zh) 2018-08-10
JP2024125234A (ja) 2024-09-13
EP4393546A2 (en) 2024-07-03
WO2016081947A2 (en) 2016-05-26
US20180291074A1 (en) 2018-10-11
JP7173733B2 (ja) 2022-11-16
JP2018502828A (ja) 2018-02-01
JP2023055625A (ja) 2023-04-18
US20200040049A1 (en) 2020-02-06
CA2968059A1 (en) 2016-05-26
CN107206064A (zh) 2017-09-26
AU2015349644B2 (en) 2021-08-19
US10993998B2 (en) 2021-05-04
EP3220950A4 (en) 2018-08-29
JP2020196732A (ja) 2020-12-10
AU2015349644A1 (en) 2017-06-15
EP4393546A3 (en) 2024-12-11
WO2016081947A3 (en) 2016-07-07
US20210308241A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
US12485162B2 (en) Determinants of cancer response to immunotherapy by pd-1 blockade
RU2707530C2 (ru) Детерминанты ответа раковой опухоли на иммунотерапию
US20220340663A1 (en) Tumor mutational load
US11274342B2 (en) Systems and methods for sequencing T cell receptors and uses thereof
JP2020525030A (ja) 癌の免疫療法への適合性を評価する方法
Hubbard et al. Safety and activity of PolyPEPI1018 combined with maintenance therapy in metastatic colorectal cancer: an open-label, multicenter, phase Ib study
CA3159747A1 (en) Hla class i sequence divergence and cancer therapy
CN115135386A (zh) 用于治疗胶质母细胞瘤的方法
HK40115175A (en) Determinants of cancer response to immunotherapy by pd-1 blockade
HK40032690A (en) Tumor mutational load and checkpoint immunotherapy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment